Mazdutide (also known in research literature as IBI362 or LY3305677) from Super Human Peptides UK is a highly advanced, long-acting synthetic peptide. It is specifically engineered as a dual agonist of both the Glucagon-Like Peptide-1 receptor (GLP-1R) and the Glucagon receptor (GCGR), structurally modeled after the naturally occurring mammalian hormone oxyntomodulin (OXM). In laboratory research, Mazdutide represents a powerful alternative to single-target incretin models.
While GLP-1 activation primarily regulates appetite and insulin secretion, researchers utilize the simultaneous GCGR activation of Mazdutide to pharmacologically force an increase in basal metabolic rate and lipolysis (fat oxidation). To achieve a prolonged half-life suitable for sustained study, the peptide is structurally modified with a C19 fatty acid (nonadecanoic acid) side chain. Produced under GMP-compliant conditions and verified for 99% purity or higher, Mazdutide is a premier model for investigating severe obesity, profound hepatic steatosis (liver fat) clearance, and comprehensive metabolic syndrome reversal.
- —Oxyntomodulin Analogue: Mimics the endogenous gut hormone responsible for dual satiety and energy expenditure signaling.
- —Dual Agonist (GLP-1 / GCGR): Simultaneously suppresses appetite while actively stimulating metabolic fat-burning pathways.
- —Engineered Half-Life: Conjugated with a C19 fatty acid side chain to protect against rapid enzymatic degradation.
- —Liver Fat Clearance: Studied for exceptionally rapid reductions in hepatic triglycerides.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Synergistic Receptor Engagement: Studying the delicate balance of activating GLP-1 receptors to control glycaemic load while using GCGR activation to prevent the suppression of metabolic rate typically seen during weight loss.
- —Energy Expenditure: Measuring the pharmacological induction of thermogenesis and the shifting of the body’s primary fuel source to oxidized fatty acids.
- —Hepatic Steatosis: Preclinical and early-phase clinical modeling of the rapid clearance of liver fat and reduction of systemic uric acid.
- —Lipid Profile Modulation: Investigating significant reductions in circulating triglycerides and LDL cholesterol under high-fat diet conditions.
- —Satiety and Gastric Emptying: Evaluating the delayed transit of nutrients through the gastrointestinal tract and the corresponding downstream neurological signals for fullness.
Mazdutide was co-developed by Eli Lilly and Innovent Biologics to harness the unique, dual-action power of oxyntomodulin, a hormone that naturally reduces food intake while increasing energy expenditure. In groundbreaking laboratory and advanced phase clinical trials (such as the GLORY-1 study), Mazdutide demonstrated staggering metabolic efficacy. Researchers noted that unlike GLP-1 mono-agonists, which rely almost entirely on caloric deficit for weight reduction, Mazdutide actively drives the body to burn more calories at rest via the glucagon pathway.
Animal models and human trials consistently show massive reductions in body weight (exceeding 15-20% in prolonged studies), alongside profound improvements in cardiovascular risk factors and up to an 80% reduction in liver fat. Because it effectively combats metabolic adaptation (the slowing of metabolism during weight loss), it is highly prioritized in modern endocrine research.
- 1.Ji, L. et al., "A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes," Nature Communications, 2022.
- 2.Jiang, H. et al., "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial," eClinicalMedicine, 2022.
- 3.Deng, C.X. et al., "Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity," World Journal of Pharmacology, 2026.
